2020

# Retinal Imaging in Alzheimer's and Neurodegenerative Diseases

Peter J. Snyder
*University of Rhode Island*, pjsnyder@uri.edu

Jessica Alber
*University of Rhode Island*, jalber@uri.edu

Clemens Alt

Lisa J. Bain

Brett E. Bouma

*See next page for additional authors*

## Citation/Publisher Attribution

## Authors

Peter J. Snyder, Jessica Alber, Clemens Alt, Lisa J. Bain, Brett E. Bouma, Femke H. Bouwman, Delia Cabrera DeBuc, Melanie C.W. Campbell, Maria C. Carrillo, Emily Y. Chew, M. Francesca Cordeiro, Michael R. Dueñas, Brian M. Fernández, Maya Koronyo-Hamaoui, Chiara La Morgia, Roxana O'Carare, Srinivas R. Sadda, Peter van Wijngaarden, and Heather M. Snyder

---

to read: "Chief Public Health Officer, American Optometric Association, Washington, D.C."

biological changes associated with AD, and for tracking progression of disease severity over time. As different retinal imaging modalities provide different types of structural and/or functional information, the discussion reflected on these modalities and their respective strengths and weaknesses. Discussion further focused on the importance of defining the context of use to help guide the development of retinal biomarkers. Moving from research to context of use, and ultimately to clinical evaluation, this article outlines ongoing retinal imaging research today in Alzheimer's and other brain diseases, including a discussion of future directions for this area of study.

**KEYWORDS**

Alzheimer's disease, biomarkers, early detection, eye, neurodegeneration, retina, retinal imaging